

References

- * www.ustransplant.org accessed in June, 2006.
- ** **National Cholesterol Education Program (NCEP) and Adult Treatment Panel (ATP) III for the general population.**
- *****G. Guidelines for the prevention and Management of infectious complications of solid organ transplantation.** *Am J Transplant* 2004; 4(Suppl. 10); 66–71.
- Aakhus S, Dahl K, Wideroe TE.** Hyperlipidaemia in renal transplant patients. *J Intern Med* 1996; 239: 407.
- Abbott KC, Hypolite I, Poropatich RK, et al.** Hospitalizations for fungal infections after renal transplantation in the United States. *Transpl Infect Dis* 2001; 3(4): 203-11.
- Abbud-Filho M, Adams PL, Alberu J, et al.** A report of the Lisbon conference on the care of the kidney transplant recipient. *Transplantation* 2007; 83: S1.
- Abramowicz D, Del Carmen Rial M, Vitko S, et al.** Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. *J Am Soc Nephrol* 2005; 16: 2234.
- Afzali B, Lombardi G, Lechler RI, Lord GM.** The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. *Clin Exp Immunol* 2007; 48(1): 32–46.
- Ahmed Z, Marshall MB, Kucharczuk JC, et al.** Lung cancer in transplant recipients: a single-institution experience. *Arch Surg* 2004; 139: 902.
- Ahsan N, et al.** Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. *Steroid Withdrawal Study Group.* *Transplantation* 1999; 68: 1865.
- Albrecht T, Blomley M, Bolondi L, et al.** Guidelines for the use of contrast agents in ultrasound. *Ultraschall Med* (2004) 25: 249–256

- Alexander JW, Metze TJ, McIntosh MJ, et al.** The influence of immunomodulatory diets on transplant success and complications. *Transplantation* 2005; 79: 460.
- Almond PS, Matas A, Gillingham K, et al.** Risk factors for chronic rejection in renal allograft recipients. *Transplantation* 1993; 55: 752.
- Altiparmak MR, Apaydin S, Trablus S, et al.** Systemic fungal infections after renal transplantation. *Scand J Infect Dis* 2002; 34(4): 284-8.
- American Association of Tissue Banks: provisional guidelines for cell, tissue, and organ preservation.** *American Association of Tissue Banks Newsletter*.1980; 4: 25-43.
- Amgad E El-Agroudy, Khaled El-Dahshan, Khaled Mahmoud, Mohamed A Ghoneim:** Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications, *Ann Transplant*. 2008;13(4):46-54
- Anderson DJ, Schmidt C, Goodman J, Pomeroy C.** Cryptococcal disease presenting as cellulitis. *Clin Infect Dis* 1992; 14: 666-72.
- Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF.** Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. *Am J Kidney Dis* 1998; 32: 582
- Andresdottir MB, Hoitsma AJ, Assmann KJ, et al.** The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. *Transplantation* 1999; 68: 623.
- Angeles C, Lane BP, Miller F, Nord EP.** Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. *Am J Kidney Dis* 2004; 44: 543.
- Antony, S.** Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. *Clin Infect Dis* 2004; 39: 879-80.
- Arrazola, Suzen H, umar A:** Dath with functioning graft;the next major hurdle, *Transplantation proceeding* 2000; 32: 1382

References

- Arsend SM, Mallat MJ, Westen drop R:** patient survival after renal transplantation, more than 25 years follow up, Nephro dialysis Transplantation, 1997; 12: 1672-1679
- Artis WM, Fountain JA, Delcher HK, Jones HE.** A mechanism of susceptibility of mucormycosis in diabetic ketoacidosis: transferrin and iron availability. *Diabetes* 1982; 31: 1109-14.
- Artz, MA, et al.** Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. *J Am Soc Nephrol* 2003; 14: 1880.
- Artz MA, Hilbrands LB, Borm G, et al.** Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. *Nephrol Dial Transplant* 2004; 19: 2852
- Asberg A, Holdaas H, Jardine AG, et al.** Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. *Clin Transplant* 2003; 17: 385.
- Aseni P, Vertemati M, Minola E, et al.** Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. *Liver Transpl* 2001; 7: 816.
- Bachmann K, Jauregui L, Chandra R, Thakker K.** Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. *Pharmacol Res* 2003; 47(6): 549-54.
- Bakker RC, Hollander, AA, Mallat, MJ, et al.** Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. *Kidney Int* 2003; 64: 1027.
- Barrett WL, First MR, Aron BS, Penn I.** Clinical course of malignancy in renal transplant recipients. *Cancer* 1993; 72: 2186.
- Barrou B, Bitker MO, Boyer C, Sylla C, Chatelain C.** Results of renal transplantation in patients with *Schistosoma* infection. *J Urol* 1997; 157(4): 1232-5.
- Basadonna GP, Matas AJ, Gillingham KJ, et al.** Early versus late acute renal allograft rejection: Impact on chronic rejection. *Transplantation* 1993; 55: 993

References

- Bavinck JN, Tieben LM, Van der Woude FJ, et al.** Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. *J Clin Oncol* 1995; 13: 1933.
- Beaman BL, Black CM, Doughty F, Beaman L.** Role of superoxide dismutase and catalase as determinants of pathogenicity of *Nocardia asteroides*: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. *Infect Immun* 1985; 47: 135-41.
- Benigni A, Bruzzi I, Mister M, et al.** Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. *Kidney Int* 1999; 55: 674.
- Berenguer J, Gomez-Campdera F, Padilla B, et al.** Visceral leishmaniasis (Kala-Azar) in transplant recipients: case report and review. *Transplantation* 1998; 65(10): 1401-04.
- Berg AL, Nilsson-Ehle P.** ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. *Kidney Int* 1996; 50: 538.
- Berg D, Otley CC.** Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002; 47: 1
- Berthoux FC, Guerin C, Burgard G, et al.** One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. *Transplant Proc* 1992; 24:2578.
- Bhathena DB.** Glomerular size and the association of focal glomerulosclerosis in long-surviving human renal allografts. *J Am Soc Nephrol* 1993; 4: 1316.
- Birkeland SA, Storm HH.** Risk for tumor and other disease transmission by transplantation: A population-based study of unrecognized malignancies and other diseases in organ donors. *Transplantation* 2002; 74:1409.
- Blair JE, Logan JL.** Coccidioidomycosis in solid organ transplantation. *Clin Infect Dis* 2001; 33(9): 1536-44

References

- Boivin G, Goyette N, Gilbert C, et al.** Absence of CMV-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid organ transplant recipients. *J Infect Dis* 2004; 189: 1615-8.
- Boots JM, Christiaans MH, Van Duijnhoven EM, et al.** Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. *Transplantation* 2002; 74: 1703.
- Bordea C, Wojnarowska F, Millard PR, et al.** Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. *Transplantation* 2004; 77: 574.
- Boudreaux JP, McHugh L, Canafax DM, et al.** The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. *Transplantation* 1987; 44: 376.
- Bouwes Bavinek JN, Feltkamp M, Struijk L, Ter Schegget J.** Human papillomavirus infection and skin cancer risk in organ transplant recipients. *J Invest Dermatol Symp Proc* 2001; 6:207.
- Boxman ILA, Berkhout RJ, Mulder LH, et al.** Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. *J Invest Dermatol* 1997; 108: 712.
- Boyer O, Le Bidois J, Dechaux M, et al.** Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. *Transplantation* 2005; 79: 1405.
- Bradley JR, Wreghitt TG, Evans DB.** Chickenpox in adult renal transplant recipients. *Nephrol Dial Transplant* 1987; 1(4): 242-5.
- Brenner BM, Cohen RA, Milford EL.** In renal transplantation, one size may not fit all. *J Am Soc Nephrol* 1992; 3: 162.
- Brenner BM, Milford EL.** Nephron underdosing: A programmed cause of chronic renal allograft failure. *Am J Kidney Dis* 1993; 21: 66.
- Briganti EM, Russ GR, McNeil JJ, et al.** Risk of renal allograft loss from recurrent glomerulonephritis. *N Engl J Med* 2002; 347: 103.

References

- Briggs ID:** causes of death after renal transplantation, NDT 2001; 16: 1545-1549.
- Broeders N, et al.** Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15: 1993.
- Bryan CF, Mitchell SI, Lin HM, et al.** Influence of the Rh (D) blood group system on graft survival in renal transplantation. Transplantation 1998; 65: 588.
- Buchanan C, Smith L, Corbett J, et al.** A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770.
- Buell JF, Gross TG, Woodle ES.** Malignancy after transplantation. Transplantation 2005; 80: S254.
- Burdmann EA, Andoh TF, Nast CC, et al.** Prevention of experimental cyclosporine-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491.
- Burdmann EA, Andoh TF, Yu L, Bennett WM.** Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465.
- Butler JA, Roderick P, Mullee M, et al.** Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769.
- Butterly DW, Spurney RF, Ruiz P, et al.** A role for leukotrienes in cyclosporine nephrotoxicity. Kidney Int 2000; 57: 2586.
- Caforio AL, Fortina AB, Piaserico S, et al.** Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102: III222.
- Caillard S, Agodoa LY, Bohlen EM, Abbott KC.** Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81:888.
- Campistol JM, Eris J, Oberbauer R, et al.** Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581

References

- Campistol JM, Gutierrez-Dalmau A, Torregrosa JV.** Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. *Transplantation* 2004; 77: 760.
- Cavusoglu C, Cicek-Saydam C, Karasu Z, et al.** Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. *Clin Transplant* 2002; 16(4): 257-61.
- Cecka JM, Cho L.** Sensitization. In: *Clinical Transplants 1988*, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1989, p.365.
- Chan PC, Chen IK, Wong KK, Lin K.** Urinary tract infections in post-renal transplant patients. *Int Urol Nephrol* 1990; 22(4): 389-96.
- Chandraker A, Takada M, Nadeau K, et al.** CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. *Kidney Int* 1997; 52: 1678.
- Chapman JR, Nankivell BJ.** Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?. *Nephrol Dial Transplant* 2006; 21: 2060.
- Chapman JR, O'Connell PJ, Nankivell BJ.** Chronic renal allograft dysfunction. *J Am Soc Nephrol* 2005; 16: 3015.
- Charra B, Calemard E, Ruffet M, et al.** Survival as an index of adequacy of dialysis. *Kidney Int* 1992; 41: 1286.
- Chrysostomou A, Walker RG, Russ GR, et al.** Diltiazem in renal allograft recipients receiving cyclosporine. *Transplantation* 1993; 55: 300.
- Ciancio G, Burke GW, Gaynor JJ, et al.** A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. *Transplantation* 2004; 77: 252.
- Ciancio G, Burke GW, Gaynor JJ, et al.** A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. *Transplantation* 2006; 81:845.

References

- Cofan F, Gilabert R, Zambon D, et al.** Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. *Transplant Proc* 2002; 34: 384.
- Cooper SM, Wojnarowska F.** The accuracy of clinical diagnosis of suspected premalignant and malignant skin lesions in renal transplant recipients. *Clin Exp Dermatol* 2002; 27:436.
- Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC.** Interrelationships among quantity of HCMV DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. *J Infect Dis* 1997; 176: 1484-90.
- Cosio FG, Pesavento TE, Osei K, et al.** Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. *Kidney Int* 2001; 59: 732.
- Cowen EW, Billingsley EM.** Awareness of skin cancer by kidney transplant patients. *J Am Acad Dermatol* 1999; 40: 697.
- Cox NJ, Subbarao K.** Influenza. *Lancet* 1999; 354(9186): 1277-82.
- Cui Y, et al.** Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med* 2001; 161: 1413.
- Curtis JJ, Laskow DA, Jones PA, et al.** Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. *J Am Soc Nephrol* 1993; 3: 1570.
- Curtis JJ, Luke RG, Diethelm AG, et al.** Benefits of removal of native kidneys in hypertension after renal transplantation. *Lancet* 1985; 2: 739.
- Cuvelier R, Pirson Y, Alexandre GP, van Ypersele DS.** Late urinary tract infection after transplantation: prevalence, pre-disposition and morbidity. *Nephron* 1985; 40(1): 76-8.
- Dantal J, Hourmant M, Cantarovich D, et al.** Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. *Lancet* 1998; 351: 623

References

- Dantal J, Souillou JP.** Immunosuppressive drugs and the risk of cancer after organ transplantation. *N Engl J Med* 2005; 352: 1371.
- Davidson J, Wilkinson A, Dantal J, et al.** New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation* 2003; 75: SS3.
- Davies SF, Sarosi GA, Peterson PK, et al.** Disseminated histoplasmosis in renal transplant recipients. *Am J Surg* 1979; 137(5): 686-691.
- de Fijter, JW, Mallat MJ, Doxiadis, II, et al.** Increased immunogenicity and cause of graft loss of old donor kidneys. *J Am Soc Nephrol* 2001; 12: 1538.
- de Jong-Tieben LM, Berkhout RJ, ter Schegget J, et al.** The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. *Transplantation* 2000; 69: 44.
- de Mattos AM, Olyaei AJ, Prather JC, et al.** Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. *Kidney Int* 2005; 67: 714.
- de Vries AP, Bakker SJ, van Son WJ, et al.** Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. *Am J Transplant* 2004; 4: 1675.
- Delmonico FL, Syndman DR.** Organ donor screening for infectious diseases,transplantation 1998;65:603-610.
- Delmonico FL.** Cadaver donor screening for infectious agents in solid organ transplantation. *Clin Infect Dis.* 2000; 31: 781-6.
- Denton MD, et al.** Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. *Kidney Int* 2002; 61: 2201.
- Dhar JM, al Khader AA, et al.** Sulaiman M, al Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. *J Med* 1991; 78(287): 235-50.

References

- Diaz Encarnacion MM, Griffin MD, Slezak JM, et al.** Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. *Am J Transplant* 2004; 4: 248.
- Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M.** Cytomegalovirus infection and graft rejection in renal transplantation. *Transplantation* 2001; 71(6): 764-7.
- Doublet JD, Peraldi MN, Gattegno B, et al.** Renal cell carcinoma of native kidneys: Prospective study of 129 renal transplant patients. *J Urol* 1997; 158: 42.
- Drachenberg CB, Klassen DK, Weir MR, et al.** Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. *Transplantation* 1999; 68: 396.
- Dreno B, Mansat E, Legoux B, Litoux P.** Skin cancers in transplant patients. *Nephrol Dial Transplant* 1998; 13: 1374.
- Ducloux D, Carron P-L, Rebibou J-M, et al.** CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. *Transplantation* 1998; 65: 1270.
- Ducloux D, Kazory A, Chalopin JM.** Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: A prospective study. *Transplantation* 2005; 79: 438.
- Edmond O'Riordan.** Renal and Urinary Proteomics *Proteomics* 2008 volume 2 issue 7-8, pages 1025-1035.
- Edwards JE Jr, Bodey GP, Bowden RA, et al.** International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 1997; 25(1): 43-59.
- Elsner HA, Tenschert W, Fisher L, Kaulfers PM.** Nosocomial infections by *Listeria monocytogenes*: analysis of a cluster of septicemias in immunocompromised patients. *Infection* 1997; 25(3): 135-9.
- Emond JP, Marcelin AG, Dorent R, et al.** Kaposi's sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. *J Clin Microbiol* 2002; 40: 2217.

References

- Emre S, Genyk Y, Schluger LK, et al.** Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. *Transpl Int* 2000; 13:73.
- Engl T, Makarevic J, Relja B, et al.** Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. *BMC Cancer* 2005; 5: 4.
- Enke BU, Bokenkamp A, Offner G, Bartmann P, Brodehl J.** Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. *Transplantation* 1997; 64(2): 237-41.
- Escofet X, Osman H, Griffiths DF, et al.** The presence of glomerular sclerosis at time zero has a significant impact on function after cadaveric renal transplantation. *Transplantation* 2003; 75: 344.
- Euvrard S, Chardonnet Y, Pouteil-Noble C, et al.** Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. *Cancer* 1993; 72: 2198.
- Euvrard S, Kanitakis J, Chardonnet Y, et al.** External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. *Arch Dermatol* 1997; 133: 175.
- Euvrard S, Kanitakis J, Claudy A.** Skin cancers after organ transplantation. *N Engl J Med* 2003; 348: 1681.
- Euvrard S, Kanitakis J, Decullier E, et al.** Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. *Transplantation* 2006; 81: 1093.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).** *Jama* 2001; 285: 2486.
- Fabrizi F, Martin P, Dixit V, et al.** Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. *Am J Transplant* 2005; 5: 2433.
- Farge D.** Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. *Eur J Med* 1993; 2: 339.

References

- Fehr T, Bossart W, Wahl C, Binswanger U.** Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. *Transplantation* 2002; 73(4): 608-11.
- Fellstrom B, Holdaas H, Jardine AG, et al.** Risk factors for reaching renal endpoints in the assessment of lescol in renal transplantation (ALERT) trial. *Transplantation* 2005; 79: 205.
- Fenig E, Brenner B, Rakowsky E, et al.** Classic Kaposi sarcoma: Experience at Rabin Medical Center in Israel. *Am J Clin Oncol* 1998; 21: 498.
- Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al.** The risk of cardiovascular disease associated with proteinuria in renal transplant patients. *Transplantation* 2002; 74: 1345, 1349.
- Fernandez-Guerrero ML, Aguado JM, Buzon L, et al.** Visceral leishmaniasis in immunocompromised hosts. *Am J Med* 1987; 83(6): 1098-102.
- Feutren G, Mihatsch MJ.** For the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. *N Engl J Med* 1992; 326: 1654.
- First MR, Neylan JF, Rocher LL, Tejani A.** Hypertension after renal transplantation. *J Am Soc Nephrol* 1994; 4: S30.
- First MR, Neylan JF, Rocher LL, Tejani A.** Hypertension after renal transplantation. *J Am Soc Nephrol* 1994; 4: S30.
- Fishman JA.** Infection in Renal Transplant Recipients Seminars in Nephrology, Vol 27, No 4, July 2007, pp 445-461.
- Fischereder M, Luckow B, Hoher B, et al.** CC chemokine receptor 5 and renal-transplant survival. *Lancet* 2001; 357: 1758
- Fishman JA, Rubin RH.** Infection in organ-transplant recipients. *N Engl J Med* 1998; 338: 1741.
- Flechner SM, Kurian SM, Solez K, et al.** De Novo Kidney Transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. *Am J Transplant* 2004; 4: 1776.

References

- Flechner SM, Kurian SM, Head SR et al.** Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. *Am J Transplant* 2004; 4: 1475–1489.
- Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE.** Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. *Adv Perit Dial* 1999; 15: 269-72.
- Foley RN, Parfrey PS, Sarnak, MJ.** Epidemiology of cardiovascular disease in chronic renal disease. *J Am Soc Nephrol* 1998; 9: S16.
- Fong TL, Bunnapradist S, Jordan SC, Cho YW.** Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of united network of organ sharing database between 1994 and 1999. *Transplantation* 2002; 73(1): 85-9.
- Fontaine H, Thiers V, Chretien Y, et al.** HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. *Transplantation* 2000; 69(10): 2090-4
- Formica RN Jr, Friedman AL, Lorber MI, et al.** A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. *Nephrol Dial Transplant* 2006; 21: 1389.
- Frances C, Mouquet C, Marcelin AG, et al.** Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. *Transplantation* 2000; 69: 1776.
- Frances C.** Kaposi's sarcoma after renal transplantation. *Nephrol Dial Transplant* 1998; 13: 2768.
- Frantz RP, Edwards BS, Olson LJ, et al.** Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients. *Transplantation* 1997; 63: 1607.
- Fricke L, Doehn C, Steinhoff J, et al.** Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? *Transplantation* 1998; 65: 1182
- Friedlaender MM, Rubinger D, Rosenbaum E, et al.** Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. *Transplantation* 2002; 73: 1849.

References

- Friedman AN, Miskulin DC, Rosenberg IH, Levey AS.** Demographics and trends in overweight and obesity in patients at time of kidney transplantation. *Am J Kidney Dis* 2003; 41: 480.
- Friedman EA, Shyh TP, Beyer MM, et al.** Posttransplant diabetes in kidney transplant recipients. *Am J Nephrol* 1985; 5: 196.
- Frimat L, Villemot J-P, Cormier L, et al.** Treatment of end-stage renal failure after heart transplantation. *Nephrol Dial Transplant* 1998; 13: 2905.
- Gaston RS, Basadonna G, Cosio FG, et al.** Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. *Am J Kidney Dis* 2004; 44: 529.
- Gaston RS, Hudson SL, Julian BA, et al.** Impact of donor/recipient size matching on outcomes in renal transplantation. *Transplantation* 1996; 61: 383.
- Gaston RS, Julian BA, Curtis JJ.** Posttransplant erythrocytosis: An enigma revisited. *Am J Kidney Dis* 1994; 24: 1.
- Gerster JC, Dudler M, Halkic N, Gillet M.** Gout in liver transplant patients receiving tacrolimus. *Ann Rheum Dis* 2004; 63: 894.
- Ghasemian SM, Guleria AS, Khawand NY, Light JA.** Diagnosis and management of the urologic complications of renal transplantation. *Clin Transplant* 1996; 10: 218-23.
- Gibbons LW, et al.** The prevalence of side effects with regular and sustained-release nicotinic acid. *Am J Med* 1995; 99: 378.
- Giblin L, O'Kelly P, Little D, et al.** A comparison of long-term graft survival rates between the first and second donor kidney transplanted--the effect of a longer cold ischaemic time for the second kidney. *Am J Transplant* 2005; 5: 1071.
- Goldstein DJ, Austin JH, Zuech N, et al.** Carcinoma of the lung after heart transplantation. *Transplantation* 1996; 62: 772.
- Gombert ME, Josephson A, Goldstein EJ, Smith PR, Butt KM.** Cavitory Legionnaires' pneumonia: nosocomial infection in renal transplant recipients. *Am J Surg* 1984; 147(3): 402-5.

References

- Halloran PF, Langone AJ, Helderman JH, Kaplan B.** Assessing long-term nephron loss: is it time to kick the CAN grading system? *Am J Transplant* 2004; 4: 1729.
- Halloran PF, Melk, A, Barth, C.** Rethinking chronic allograft nephropathy: The concept of accelerated senescence. *J Am Soc Nephrol* 1999; 10:167.
- Hamdy AF, Bakr MA, Ghoneim MA.** Long term efficacy and safety of calcineurine inhibitor free regimens in a live-donor renal transplant recipients *J Am Soc Nephrol*. 2008 Jun; 19(6): 1225-32
- Hariharan S, Adams MB, Brennan DC, et al.** Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). *Transplantation* 1999; 68: 635.
- Hariharan S, Johnson CP, Bresnahan BA, et al.** Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Engl J Med* 2000; 342: 605
- Hariharan S, McBride MA, Cherikh WS, Tolleris CB.** Post-transplant renal function in the first year predicts long-term kidney transplant survival. *Kidney Int* 2002; 62: 311

References



Hebert PR, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. *Jama* 1997; 278: 313.

Heine GH, Gerhart MK, Ulrich C, Kohler H, Girndt M. (Renal Doppler resistance indices are associated with systemic atherosclerosis in kidney transplant recipients. *Kidney Int*: 2005; 68: 878-885.

Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Type 1 Receptor Antagonist Therapy Is Associated with Prolonged Patient and Graft Survival after Renal Transplantation. *J Am Soc Nephrol* 2006; 17: 889.

Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. *Am J Transplant* 2004; 4: 583.

Helanterä I, Koskinen P, Tornroth T, Loginov R, Gronhagen-Riska C, Lautenschlager I. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. *Transplantation* 2003; 75(11): 1858-64.

References

- Hibberd PL, Rubin RH.** Renal transplantation and related infections. *Semin Respir Infect* 1993; 8(3): 216-24.
- Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al.** Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. *Transplantation* 1992; 53(1): 68-72.
- Hibberd PL, Tolkoff-Rubin NE, Doran M, et al.** Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. *Online J Curr Clin Trials* 1992; Doc No 15:4083 words; 46 paragraphs.
- Hill MN, Grossman RA, Feldman HI, et al.** Changes in causes of death after renal transplantation, 1966 to 1987. *Am J Kidney Dis* 1991; 17: 512.
- Hirsch IB, Paauw DS.** Diabetes management in special situations. *Endocrinol Metab Clin North Am* 1997; 26: 631.
- Hjelmesaeth J, Hartmann A, Kofstad J, et al.** Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. *Transplantation* 1997; 64: 979.
- Hjelmesaeth J, Hartmann A, Kofstad J, et al.** Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. *Nephrol Dial Transplant* 2001; 16: 829.
- Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A.** Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. *Diabetes Care* 2001; 24: 2121.
- Ho M.** Immunology of cytomegalovirus: immunosuppressive effects during infections. *Birth defects: Original Article Series* 1984; 20(1): 131-47.
- Hocker B, Feneberg R, Kobfs.** pediatric transplantation 2006 August; 10(5) 593-601
- Hojo M, Morimoto T, Maluccio M, et al.** Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature* 1999; 397: 530.

References

- Holdaas H, Fellstorm B, Jardine A, et al.** Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomised, placebo-controlled trial. *Lancet* 2003;361:2024-2031, P.278.
- Holdaas H, Fellstrom B, Cole E, et al.** Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. *Am J Transplant* 2005; 5: 2929.
- Hollander AA, Hene RJ, Hermans J, et al.** Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. *J Am Soc Nephrol* 1997; 8: 294.
- Holman MJ, Gonwa TA, Cooper B, et al.** FK506-associated thrombotic thrombocytopenic purpura. *Transplantation* 1993; 55: 205.
- Homan van der Heide JJ, Bilo HJ, Tegzess AM, Donker AJ.** The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. *Transplantation* 1990; 49: 523.
- Hoogeveen RC, et al.** Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. *Transplantation* 2001; 72:1244.
- Hoogwerf B, Danese, RD.** Drug selection and the management of corticosteroid-related diabetes mellitus. *Rheum Dis Clin North Am* 1999; 25: 489.
- Hornef MW, Bein G, Friche L, et al.** Coincidence of EBV reactivation, CMV infection, and rejection episodes in renal transplant recipients. *Transplantation* 1995; 60: 474-80.
- Hori S, Nomura T, Sakaguchi S.** Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; 299 (5609): 1057-61
- Hostetter TH.** Chronic transplant rejection. *Kidney Int* 1994; 46: 266.
- Hoy WE, Kissel SM, Freeman RB, Sterling WA Jr.** Altered patterns of posttransplant urinary tract infections associated with perioperative antibiotics and curtailed catheterization. *Am J Kidney Dis* 1985; 6(4): 212-6.

References

- Hricik DE, et al.** The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. *Transplantation* 1992; 54: 868.
- Hricik DE, Lautman J, Bartucci MR, et al.** Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine treated renal transplant recipients. *Transplantation* 1992; 53: 1232
- Hricik DE, Mayes JT, Schulak JA.** Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. *Am J Kidney Dis* 1991; 18: 353.
- Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ.** Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. *Transplantation* 1999; 68(12): 1879-83.
- Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ.** Are wound complications after a kidney transplant more common with modern immunosuppression? *Transplantation* 2001; 72(12): 1920-3.
- Humar A, Kerr S, Gillingham KJ, Matas AJ.** Features of acute rejection that increase risk for chronic rejection. *Transplantation* 1999; 68: 1200.
- Humar A, Payne WD, Sutherland DE, Matas AJ.** Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. *Transplantation* 2000; 69: 2357
- Hunley TE, Fogo A, Iwasaki S, Kon V.** Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. *J Am Soc Nephrol* 1995; 5: 1718.
- Hussein A. Sheashaa Mohamed A. Bakr Mohamed A. Sobh Mohamed A. Ghoneim.** Long-Term Evaluation of Basiliximab Induction Therapy in Live Donor Kidney Transplantation: A Five-Year Prospective Randomized Study *Am J Nephrol* 2005; 25: 221-225
- Husain S, Waener MM, Singh N.** Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. *Emerg Infect Dis* 2001; 7(3): 375-81.

References

- Islam M, Burke JF Jr, McGowan TA, et al.** Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. *Kidney Int* 2001; 59: 498.
- Isoniemi.** Histopathological findings in well-functioning long-term renal allograft. *Kidney International* 1992; 41, 155-160.
- Jamil B, Nicholls K, Becker GJ, Walker RG.** Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. *Transplantation* 1999; 68(10): 1597-1603.
- Jardine AG, Holdaas H, Fellstrom B, et al.** Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-Hoc subgroup analyses of the ALERT study. *Am J Transplant* 2004; 4:988.
- Jassal SV, Roscoe JM, Zaltzman JS, et al.** Clinical practice guidelines: prevention of CMV disease after renal transplantation. *J Am Soc Nephrol*.1998; 9: 1697-708.
- Jemec GB, Holm EA.** Nonmelanoma skin cancer in organ transplant patients. *Transplantation* 2003; 75: 253.
- Jha V, Kohli HS, Sud K, et al.** Laryngeal tuberculosis in renal transplant recipients. *Transplantation* 1999; 68(1): 153-5.
- Jindal RM, Hjelmessaeth J.** Impact and management of posttransplant diabetes mellitus. *Transplantation* 2000; 70: SS58.
- Johnson BA, Iacono AT, Zeevi A, et al.** Statin use is associated with improved function and survival of lung allografts. *Am J Respir Crit Care Med* 2003; 167: 1271.
- Johnson, C, Ahsan, N, Gonwa, T, et al.** Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. *Transplantation* 2000; 69: 834.
- Kahan BD.** Drug therapy: Cyclosporine. *N Engl J Med* 1989; 321:1725.
- Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J.** Amantadine therapy in renal transplant patients with HCV infection. *J Clin Virol* 2004; 30(1): 110-4.

References

- Kamar N, Snadres-Saune K, Selves J, et al.** Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. *Am J Kidney Dis* 2003; 42(1): 184-92.
- Kamar N, Toupance O, Buchler M, et al.** Evidence that clearance of hepatitis C virus RNA after alpha-IFN therapy in dialysis patients is sustained after renal transplantation. *J Am Soc Nephrol* 2003; 14(8): 2092-8.
- Kamath NS, John GT, Neelakantan N, et al.** Acute graft pyelonephritis following renal transplantation. *Transpl Infect Dis* 2006; 8: 140
- Kandaswamy R, Humar A, Casingal V, Ibrahim H.** Transplantation 2007 Mar 27; 38(6): 722-6.
- Kasayama S, Tanaka T, Hashimoto K, et al.** Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. *Diabetes Care* 2002; 25: 2359.
- Kasiske B, Cosio FG, Beto J, et al.** Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report of the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. *Am J Transplant* 2004; 4(Suppl 7): 13-53.
- Kasiske, B. L., Guijarro, C., Massy, Z. A., Wiederkehr, M. R., Ma, J. Z.:** Cardiovascular disease after renal transplantation. *J. Am. Soc. Nephrol.*, 7, 158, 1996.
- Kasiske, BL, Anjum, S, Shah, R, et al.** Hypertension after kidney transplantation. *Am J Kidney Dis* 2004; 43: 1071.
- Kasiske BL, et al.** A meta-analysis of immunosuppression withdrawal trials in renal transplantation. *J Am Soc Nephrol* 2000; 11: 1910.
- Kasiske BL, Gaston RS, Gourishankar S, et al.** Long-term deterioration of kidney allograft function. *Am J Transplant* 2005; 5: 1405.
- Kasiske, BL, Snyder, JJ, Gilbertson, D, Matas, AJ.** Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 2003; 3: 178.

References

- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C.** Cancer after kidney transplantation in the United States. *Am J Transplant* 2004; 4: 905.
- Kasiske BL, Vazquez MA, Harmon WE, et al.** Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. *J Am Soc Nephrol* 2000; 11 Suppl 15: S1.
- Kasiske BL.** Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 1988; 84: 985.
- Katznelson S, et al.** The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. *Transplantation* 1996; 61: 1469.
- Kauffman HM, Cherikh WS, Cheng Y, et al.** Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies. *Transplantation* 2005; 80: 883.
- Kauffman HM, McBride MA, Delmonico FL.** First report of the United Network for Organ Sharing Transplant Tumor Registry: Donors with a history of cancer. *Transplantation* 2000; 70: 1747.
- Keating MR, Guerrero MA, Daly RC, Walker RC, Davies SF.** Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. *Chest* 1996; 109(4): 1119-24
- Kim SJ, Schaubel DE, Jeffery JR, Fenton SS.** Centre-specific variation in renal transplant outcomes in Canada. *Nephrol Dial Transplant* 2004; 19: 1856.
- King CT, Chapman SW, Butkus DE.** Recurrent nocardiosis in a renal transplant recipient. *South Med J* 1993; 86(2): 225-8.
- Kirk A.** Less is more: maintenance minimization as a step toward tolerance. *Transplantation* 2003; 3: 643.
- Knechtle SJ, Pirsch JD, H Flechner J Jr, et al.** Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. *Am J Transplant* 2003; 3: 722-726.

References

- Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ.** The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients. *Am J Kidney Dis* 1997; 29(4): 608-14
- Kobashigawa JA, et al.** Effect of pravastatin on outcomes after cardiac transplantation. *N Engl J Med* 1995; 333: 621.
- Kohnle M, Pietruck F, Kribben A, et al.** Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. *Am J Transplant* 2006; 6: 205.
- Koyle MA, Ward HJ, Twomey PA, Glassock RJ, Rajfer J.** Declining incidence of wound infection in cadaveric renal transplant recipient. *Urology* 1988; 31(2): 103-6
- Koziolek MJ, Riess R, Geiger H, et al.** Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. *Kidney Int* 2001; 60: 156.
- Kraemer FB, et al.** Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. *Metabolism* 1998; 47: 555.
- Kramer BK, Montagnino G, Del Castillo D, et al.** Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. *Nephrol Dial Transplant* 2005; 20: 968.
- Kreis H, et al.** Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. *Transplantation* 2000; 69: 1252.
- Kreis H, Oberbauer R, Campistol JM, et al.** Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. *J Am Soc Nephrol* 2004; 15: 809.
- Kruger S, Mueller-Steinhardt M, Kirchner H, Kreft B.** A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. *Am J Kidney Dis* 2001; 38(6): 1264-70.
- Kumar D, Rotstein C, Miyata G, Arlen D, Humar A.** Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. *J Infect Dis* 2003; 187(10): 1639-45.

References

- Kumar D, Tellier R, Darker R.** Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening, 2003
- Kusne S, Shapiro R.** Surgical infections in immunocompromised patients: Prevention and treatment. *Adv Surg* 1998; 31: 299-323
- Kuster GM, et al.** Relation of cyclosporine blood levels to adverse effects on lipoproteins. *Transplantation* 1994; 57: 1479.
- Kuypers DR, Neumayer HH, Fritsche L, et al.** Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study. *Transplantation* 2004; 78:1204.
- Kuypers DR, Neumayer HH, Fritsche L, et al.** Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. *Transplantation* 2004; 78: 1204.
- Labarrere CA, Pitts D, Nelson DR, et al.** Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. *N Engl J Med* 1995; 333: 1111.
- Ladefoged SD, Andersen CB.** Calcium channel blockers in kidney transplantation. *Clin Transplant* 1994; 8: 128.
- Ladefoged SD, Pedersen E, Hammer M, et al.** Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: A randomized, double-blind, placebo-controlled study. *Nephrol Dial Transplant* 1994; 9: 543.
- Lafayette RA, Mayer G, Meyer TW.** The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. *J Am Soc Nephrol* 1993; 3: 1892.
- Lake KD.** New prophylactic treatment strategy for CMV disease. *Am J HealthSyst Pharm* 2003; 60 (Suppl 8): S13-6.
- Lake KD.** Management of drug interactions with cyclosporine. *Pharmacotherapy* 1991; 11: 110S.

References

- Lal SM, Hewett JE, Petroski GF, et al.** Effects of nicotinic acid and lovastatin in renal transplant recipients: a prospective, randomized, open-labeled crossover trial. *Am J Kidney Dis* 1995; 25: 616.
- Lamb SR, Stables GI, Merchant W.** Disseminated cutaneous infection with *Mycobacterium chelonae* in a patient with steroid-dependent rheumatoid arthritis. *Clin Exp Dermatol* 2004; 29(3): 254-7.
- Larson TS, Dean PG, Stegall MD, et al.** Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. *Am J Transplant* 2006; 6: 514.
- Lea JP, Sands JM, McMahon SJ, Tumlin JA.** Evidence that inhibition of Na⁺/K⁺-ATPase activity by FK506 involves calcineurin. *Kidney Int* 1994; 46: 647.
- Lebbe C, Euvrard S, Barrou B, et al.** Sirolimus conversion for patients with posttransplant Kaposi's Sarcoma. *Am J Transplant* 2006; 6: 2164.
- Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD.** Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. *Am J Kidney Dis* 2001; 38(5): 1074-81.
- Leibovich BC, Blute ML, Cheville JC, et al.** Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. *J Urol* 2004; 171: 1066
- Lentine, KL, Brennan, DC.** Statin use after renal transplantation: a systematic quality review of trial-based evidence. *Nephrol Dial Transplant* 2004; 19: 2378.
- Li Y, Li Xc, Zheng XX, et al:** Blocking both signal 1 and signal 2 of cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. *Nat Med* 1999; 5: 1298-1301.
- Lim EC, Terasaki PI, eds.** Early graft function. Los Angeles: UCLA Tissue Typing Lab., 1991. In: *Clinical Transplants 1990*, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles, 1991.

References

- Lin, J, Valeri, AM, Markowitz, GS, et al.** Angiotensin converting enzyme inhibition in chronic allograft nephropathy. *Transplantation* 2002; 73: 783.
- Linas SL, Miller PD, McDonald KM, et al.** Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys. *N Engl J Med* 1978; 298: 1440.
- Lindholm A, Albrechtsen D, Frodin L, et al.** Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. *Transplantation* 1995; 60: 451.
- Lindholm A, Ohlman S, Albrechtsen D, et al.** The impact of acute rejection episodes on long term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. *Transplantation* 1993; 56: 307.
- Ling BN and Eaton DC.** Cyclosporin A inhibits apical secretory K⁺ channels in rabbit cortical collecting tubule principal cells. *Kidney Int* 1993; 44: 974.
- Ling H, Li X, Jha S, et al.** Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: Morphologic improvement associated with functional preservation. *J Am Soc Nephrol* 2003; 14: 377.
- Linnemann CC Jr, First MR, Schiffman G.** Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. *Arch Intern Med* 1986; 146(8): 1554-6.
- Lipscombe J, et al.** Deterioration in renal function associated with fibrate therapy. *Clin Nephrol* 2001; 55:39.
- Ljungman P.** Beta-herpesvirus challenges in the transplant recipient. *J Infect Dis* 2002; 186 (Suppl.1): S99-S109.
- Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B.** Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. *J Infect Dis* 1986; 153(5): 840-7.
- Lu CY, Penfield JG, Kielar M, et al.** Hypothesis: Is renal allograft rejection initiated by the response to injury sustained during the transplant process? *Kidney Int* 1999; 55: 2157.

References

- Luan FL, Ding R, Sharma VK, et al.** Rapamycin is an effective inhibitor of human renal cancer metastasis. *Kidney Int* 2003; 63: 917.
- Lucey MR, Abdelmalek MF, Gagliardi R, et al.** A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. *Am J Transplant* 2005; 5: 1111.
- Lut ZJ, Huang H, Denge M, Wagner B,** *Transplantation* 2007 Mar 27; 38(6); 741
- Luther P, Baldwin D Jr.** Pioglitazone in the management of diabetes mellitus after transplantation. *Am J Transplant* 2004; 4: 2135.
- Lyerova L, Lacha J, Skibova J, Teplan V, Vitko S, Schuck O.** Urinary tract infection in patients with urological complications after renal transplantation with respect to long-term function and allograft survival. *Ann Transplant* 2001; 6(2): 19-20.
- Mackenzie HS, Tullius SG, Heemann UW, et al.** Nephron supply is a major determinant of long-term renal allograft survival in rats. *J Clin Invest* 1994; 94: 2148
- Maes BD, Kuypers D, Messiaen T, et al.** Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. *Transplantation* 2001; 72: 1655.
- Mahmoud IM, Elhabashi AF, Elsayy E, El Hussein AA, Sheha GE, Sobh MA.** The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. *Am J Kidney Dis* 2004; 43(1): 131-9.
- Maluccio M, Sharma V, Lagman M, et al.** Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. *Transplantation* 2003; 76: 597.
- Mange KC, Cizman B, Joffe M, Feldman HL.** Arterial hypertension and renal allograft survival. *JAMA* 2000; 283: 633.
- Maraha B, Bonten H, van Hooff H, Fiolet H, Buiting AG, Stobberingh EE.** Infectious complications and antibiotic use in renal transplant recipients during a 1-year follow up. *Clin Microbiol Infect* 2001; 7(11): 619-25.

References

- Margreiter, R.** Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. *Lancet* 2002; 359: 741.
- Markell M.** Clinical impact of posttransplant diabetes mellitus. *Transplant Proc* 2001; 33: 19S.
- Markell M.** New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. *Am J Kidney Dis* 2004; 43: 953.
- Marr KA, Boeck M, Carter RA, Kim HW, Corey L.** Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis*
- Marsden PA.** Predicting outcomes after renal transplantation--new tools and old tools. *N Engl J Med* 2003; 349:1822004; 39: 797-802.
- Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF.** Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. *Nephrol Dial Transplant* 1993; 8: 637.
- Masterson R, Hewitson T, Leikis M, et al.** Impact of statin treatment on 1-year functional and histologic renal allograft outcome. *Transplantation* 2005; 80:332.
- Mathew T, Kreis H, Friend P.** Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. *Clin Transplant* 2004; 18:446.
- McCune TR, et al.** Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. *Transplantation* 1998; 65: 87.
- McNamara IR, Muir J, Galbraith AJ.** Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. *J Heart Lung Transplant* 2002; 21: 1201
- Meier, M, Nitschke, M, Weidtmann, B, et al.** Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: A randomized controlled trial. *Transplantation* 2006; 81: 1035.

References

- Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B.** Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. *Am J Transplant* 2004; 4: 378.
- Merville P, Berge F, Deminiere C, et al.** Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. *Am J Transplant* 2004; 4: 1769.
- Meyer T, Arndt R, Nindl I, et al.** Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. *Transpl Int* 2003; 16: 146.
- Midtvedt K, Hartmann A, Foss A, et al.** Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril. *Transplantation* 2001; 72: 1787.
- Midtvedt K, Hjelmessaeth J, Hartmann A, et al.** Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. *J Am Soc Nephrol* 2004; 15: 3233.
- Miles AM, Sumrani N, Horowitz R, et al.** Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes?. *Transplantation* 1998; 65: 380.
- Miles AMV, Sumrani N, John S, et al.** The effect of kidney size on cadaveric renal allograft outcome. *Transplantation* 1996; 61: 894.
- Miller G, Rigsby MO, Heston L, et al.** Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. *N Engl J Med* 1996; 334: 1292.
- Miller, J, Mendez, R, Pirsch, JD, Jensik, SC.** Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. *Transplantation* 2000; 69: 875.
- Monaco AP, Burke JF, Ferguson RM, et al.** Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. *Am J Kidney Dis* 1999; 33: 150.

References

- Montori VM, Basu A, Erwin PJ, et al.** Posttransplantation diabetes: a systematic review of the literature. *Diabetes Care* 2002; 25: 583.
- Moosa MR.** Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. *Medicine (Baltimore)* 2005; 84: 12.
- Morales JM, Campistol JM, Castellano G, et al.** Transplantation of kidney from donors with hepatitis C antibody in recipients with pre-transplantation anti-HCV. *Kidney Int* 1995; 47: 236.
- Morath C, Mueller M, Goldschmidt H, et al.** Malignancy in renal transplantation. *J Am Soc Nephrol* 2004; 15: 1582.
- Morduchowicz G, Shmueli D, Shapira Z, et al.** Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. *Rev Infect Dis* 1986; 8(3): 441-6.
- Moreso F, Seron D, Carrera M, et al.** Baseline immunosuppression is associated with histological findings in early protocol biopsies. *Transplantation* 2004; 78: 1064.
- Moudouni SM, Tligui M, Doublet JD, et al.** Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys. *Transplantation* 2005; 80: 865.
- Mourad G, Ribstein J, Mimran A.** Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. *Kidney Int* 1993; 43: 419.
- Mourad G, Ribstein J, Mimran A.** Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. *Kidney Int* 1993; 43: 419.
- Mulay, AV, Cockfield, S, Stryker, R, et al.** Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. *Transplantation* 2006; 82: 1153.
- Mulay AV, Hussain N, Fergusson D, Knoll GA.** Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. *Am J Transplant* 2005; 5: 1748

References

- Muller V, Becker G, Delfs M, Albrecht KH, Philipp T, Heemann U.** Do urinary tract infections trigger chronic kidney transplant rejection in man? *Clin Urol* 1998; 159(6): 1826-9.
- Murray HW, Moore JO, Luff RD.** Disseminated Aspergillosis in a renal transplant recipient. Diagnostic difficulties re-emphasized. *Johns Hopkins Med J* 1975; 137(5): 235-7.
- Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, et al.** Messenger RNA for FOXP3 in the urine of renalallograft recipients. *N Engl J Med* 2005; 353(22): 2342-51
- Muruve NA, Shoskes DA.** Genitourinary malignancies in solid organ transplant recipients. *Transplantation* 2005; 80: 709.
- Myers BD, Newton L.** Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. *J Am Soc Nephrol* 1991; 2: S45.
- Nampoory MR, Khan ZU, Johny KV, et al.** Invasive fungal infections in renal transplant recipients. *J Infect* 1996; 33(2): 95-101.
- Nankivell BJ, Borrows RJ, Fung CL, et al.** Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. *Transplantation* 2004; 78: 557.
- Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ.** The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326.
- Nankivell BJ, Chapman JR, Gruenewald SM.** Detection of chronic allograft nephropathy by quantitative doppler imaging. *Transplantation* 2002, 74: 90-96
- Nankivell BJ, Chapman JR.** Chronic allograft nephropathy: Current concepts and future directions. *Transplantation* 2006; 81: 643.
- Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.** *Exp Clin Transplant.* 2007 Dec; 5(2): 673-9.
- Nemec DK, Lederer ED, Samo T.** Candidal splenic abscess in a renal transplant recipient. *Am J Kidney Dis* 1989; 14(5): 408-11
- Neylan JF.** Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. *FK506 Kidney Transplant Study Group.* *Transplantation* 1998; 65: 515.

References

- Nickeleit V, Zeiler M, Gudat F, Thiel G.** Detection of the complement degradation product c4d in renal allografts: diagnostic and therapeutic implications. *J Am Soc Nephrol* 2002; 13: 242.
- Novitzky D, Rose AG, Cooper DK.** Injury of myocardial conduction tissue and coronary artery smooth muscle following brain death in the baboon. *Transplantation* 1988; 45: 964
- Ochiai T, Amemiya H, Watanabe K, et al.** Successful treatment of *Nocardia asteroides* infection with minocycline in kidney transplant patients. *Japanese J Surg* 1978; 8(2): 138-44.
- Ojo AO, Held PJ, Port FK, et al.** Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; 349: 931.
- Ojo AO, Leichtman AB, Punch JD, et al.** Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric renal transplant outcomes. *Am J Kidney Dis* 2000; 36: 153.
- Olyaei AJ, deMattos AM, Bennett WM.** A practical guide to the management of hypertension in renal transplant recipients. *Drugs* 1999; 58: 1011.
- Opelz G, Dohler B, Ruhstroth A.** Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. *Am J Transplant* 2004; 4: 928.
- Opelz G, Dohler B.** Improved long-term outcomes after renal transplantation associated with blood pressure control. *Am J Transplant* 2005; 5: 2725.
- Opelz G.** For the Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet* 2005; 365: 1570.
- Opelz G, Zeier M, Laux G, et al.** No Improvement of Patient or Graft Survival in Transplant Recipients Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers: A Collaborative Transplant Study Report. *J Am Soc Nephrol* 2006; 17: 3257.
- Opelz G.** Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet* 2005; 365: 1570.

References

- Opelz, G.** The benefit of exchanging donor kidneys among transplant centers. *N Engl J Med* 1988; 318: 1289.
- Orfanakis MG, Wilcox HG, Smith CB.** In vitro studies of the combined effect of ampicillin and sulfonamides on *Nocardia asteroides* and results of therapy in four patients. *Antimicrob Agents Chemother* 1972; 1: 215-20.
- Orloff SL, Stempel CA, Wright TL, et al.** Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. *Clin Transplant* 1995; 9(2): 119-24.
- Otley CC, Hirose R, Salasche SJ.** Skin cancer as a contraindication to organ transplantation. *Am J Transplant* 2005; 5: 2079.
- Owda AK, Abdallah AH, Haleem A, et al.** De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. *Nephrol Dial Transplant* 1999; 14: 2004.
- Palmer BF, Dawidson I, Sagalowsky A, et al.** Improved outcome of cadaveric renal transplantation due to calcium channel blockers. *Transplantation* 1991; 52: 640.
- Pape L, Henne T, Offner G, et al.** Computer-assisted quantification of fibrosis in chronic allograft nephropathy by picosirius red-staining: a new tool for predicting long-term graft function. *Transplantation* 2003; 76: 955.
- Parnham AP, Flexman JP, Saker BM, Thatcher GN.** Primary varicella in adult renal transplant recipients: a report of three cases plus a review of the literature. *Clin Transplant* 1995; 9(2): 115-8.
- Pascual M, et al.** A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. *Transplantation* 2003; 75: 1501.
- Paul, LC, Benediktsson, H.** Post-transplant hypertension and chronic renal allograft failure. *Kidney Int Suppl* 1995; 52: S34.
- Paya CV, Wilson JA, Espy MJ et al.** Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. *J Infect Dis* 2002; 185: 854-860.

References

- Paya C, Humar A, Dominguez E, et al.** Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of CMV disease in solid organ transplant recipients. *Am J Transplant* 2004; 4: 611-20.
- Peddi VR, Hariharan S, First MR.** Disseminated histoplasmosis in renal allograft recipients. *Clin Transplant* 1996; 10(2): 160-5.
- Pedotti P, Cardillo M, Rossini G, Arcuri V.** Incidence of cancer after kidney transplant: results from the North Italy transplant program. *Transplantation* 2003; 76: 1448.
- Periera BJ, Wright TL, Schmid CH, Levey AS.** The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. *Transplantation* 1995; 60(8): 799-805.
- Penn I, First MR.** Merkel's cell carcinoma in organ recipients. *Transplantation* 1999; 68: 1717.
- Penn I.** Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. *Cancer* 1986; 58: 611.
- Penn I.** De novo malignances in pediatric organ transplant recipients. *Pediatr Transplant* 1998; 2: 56.
- Penn I.** Donor transmitted disease: Cancer. *Transplant Proc* 1991; 23: 2629.
- Penn I.** Malignant melanoma in organ allograft recipients. *Transplantation* 1996; 61: 274.
- Penn I.** Sarcomas in organ allograft recipients. *Transplantation* 1995; 60: 1485.
- Penn I.** Why do immunosuppressed patients develop cancer? In: *CRC Critical Reviews in Oncogenesis*, Pimentel, E (Ed), CRC, Boca Raton, 1989, p. 27.
- Pereira BJ, Wright TL, Schmid CH, Levey AS.** A controlled study of HCV transmission by organ transplantation. *Lancet* 1995; 345: 484-7
- Perico N, Ruggenti P, Gaspari F, et al.** Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. *Transplantation* 1992; 54: 56.

References

- Pescovitz M.** Prevention and treatment of CMV disease in solid organ transplant recipients: the clinical and economic impact of evolving strategies. *Am J Health-Syst Pharm* 2003; 60(suppl 8): S3-4.
- Peters TG, Shaver TR, Ames JT, et al.** Cold ischemia and outcome in 17,937 cadaveric kidney transplants. *Transplantation* 1995; 59: 191.
- Pham SM, Kormos RL, Landreneau RJ, et al.** Solid tumors after heart transplantation: lethality of lung cancer. *Ann thorac Surg* 1995; 60: 1623.
- Philipp T, Legendre C, Geiger H, et al.** SECRET Obtio: Study on the evaluation of candesartan cilextil after renal transplantation (SECRET-Study). *Kidney Blood Press Res* 2004; 27(Suppl): 331.
- Pichler RH, Franceschini N, Young BA, et al.** Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. *J Am Soc Nephrol* 1995; 6: 1186.
- Pichler RH, Franceschini N, Young BA, et al.** Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. *J Am Soc Nephrol* 1995; 6: 1186.
- Pillebout E, Nochy D, Hill G, et al.** Renal histopathological lesions after orthotopic liver transplantation (OLT). *Am J Transplant* 2005; 5: 1120.
- Pinel C, Fricker-Hidalgo H, Lebeau B, et al.** Detection of circulating aspergillus fumigatus galactomannan: value and limits of the platelia test for diagnosing invasive aspergillosis. *J Clin Microbiol* 2003; 41: 2184-6.
- Polyak MM, Arrington BO, Stubenbord WT, et al.** The influence of pulsatile preservation on renal transplantation in the 1990s. *Transplantation* 2000; 69: 249
- Porayko, MK, Textor, SC, Krom, RA, et al.** Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. *Mayo Clin Proc* 1994; 69: 105.
- Port FK, Dykstra DM, Merion RM, Wolfe RA.** Trends and results for organ donation and transplantation in the United States, 2004. *Am J Transplant* 2005; 5: 843

References

- Prasad GV, Kim SJ, Huang M, et al.** Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). *Am J Transplant* 2004; 4: 1897.
- Pratschke J, Vok HD.** Brain death-associated ischemia and reperfusion injury. *Curr Opin Organ Transplant* 2004; 9: 153.
- Preiksaitis JK, Keay S.** Diagnosis and management of posttransplant lymphoproliferative disorder in solidorgan transplant recipients. *Clin Infect Dis.* 2001; 33 Suppl 1: S38-46.
- Prodinge WM, Bonatti H, Allerberger F, et al.** Legionella pneumonia in transplant recipients: a cluster of cases of eight years' duration. *J Hosp Infect* 1994; 26(3): 191-202.
- Puthenparumpil JJ, Keough-Ryan T, Kiberd M, et al.** Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. *Transplant Proc* 2005; 37: 1033.
- Quiroga I, McShane P, Koo DD, et al.** Major effects of delayed graft function and cold ischaemia time on renal allograft survival. *Nephrol Dial Transplant* 2006; 21: 1689
- Qunibi WY, al Sibai MB, Taher S, et al.** Mycobacterial infection after renal transplantation-report of 14 cases and review of the literature. *Q J Med* 1990; 77(282): 1039-60.
- Qunibi W, Al-Furayh O, Almeshari K, et al.** Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. *Transplantation* 1998; 65: 583.
- Racusen LC, Solez K, Colvin RB, et al.** The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55: 713.
- Racusen L.** Molecular techniques in transplantation. *Transplant Proc* 2004; 36: 731-732.
- Radermacher J, Mengel M, Ellis S, Stucht S.** The renal arterial resistance index and renal allograft survival. *N Engl J Med* 2003; 349: 115.

References

- Rahn KH, Barenbrock M, Fritschka E, et al.** Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. *Lancet* 1999; 354: 1415.
- Ramsay HM, Fryer AA, Hawley CM, et al.** Non-melanoma skin cancer risk in the Queensland renal transplant population. *Br J Dermatol* 2002; 147: 950.
- Rao KV, Ma J.** Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. *Transplantation* 1996; 62(12): 1765-9.
- Razonable R, Paya CV, Smith TF.** Role of the laboratory in the diagnosis and management of cytomegalovirus infection in Hematopoietic stem cell and solid-organ transplant recipients. *J Clin Micro* 2002; 40: 746-753.
- Regamey N, Tamm M, Wernli M, et al.** Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. *N Engl J Med* 1998; 339: 1358.
- Regamey N, Tamm, M, Wernli, M, et al.** Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. *N Engl J Med* 1998; 339: 1358.
- Remuzzi G, Cravedi P, Perna A, et al.** Long-term outcome of renal transplantation from older donors. *N Engl J Med* 2006; 354:343.
- Rigatto C, Foley R, Jeffery J, et al.** Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. *J Am Soc Nephrol* 2003; 14: 462.
- Rigden S, Mehls O, Gellert R.** on behalf of the scientific advisory board of the ERA-EDTA registry. Factors influencing second renal allograft survival. *Nephrol Dial Transplant* 1999; 14: 566
- Riska H, Gronhagen-Riska C, Ahonen J.** Tuberculosis and renal allograft transplantation. *Transplant Proc* 1987; 19: 4096-7.
- Robin G, Woolfson, Guy H.** The true clinical significance of renography in nephro-urology. *European Journal of Nuclear Medicine* 1997 Vol. 24, No. 5, May 1997

References

- Robson R, Cecka JM, Opelz G, et al.** Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. *Am J Transplant* 2005; 5: 2954.
- Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al.** Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. *J Am Soc Nephrol* 2006; 17: 881.
- Rostaing L, Izopet J, Baron E, et al.** Preliminary results of treatment of chronic hepatitis C with recombinant IFN-alpha in renal transplant patients. *Nephrol Dial Transplant* 1995; 10(Suppl6): 93-6.
- Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D.** Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. *Transplantation* 2000; 69(5): 991-4.
- Rubin RH.** Infectious disease complications of renal transplantation. *Kidney Int* 1993; 44:221.
- Ruiz JC, Campistol JM, Grinyo JM, et al.** Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. *Transplantation* 2004; 78: 1312
- Russ G, Segoloni G, Oberbauer R, et al.** Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. *Transplantation* 2005; 80: 1204.
- S. Aker et al, 1998** *International Urology and Nephrology*
- Saeian K, Franco J, Komorowski RA, Adams MB.** Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. *Liver Transpl Surg* 1999; 5: 46.
- Sagedal S, Hartmann A, Nordal KP, et al.** Impact of early cytomegalovirus infection and disease in long-term recipient and kidney graft survival. *Kidney Int* 2004; 66: 329-37.
- Sahu K, Sharma R, Gupta A, et al.** Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. *Clin Transplant* 2001; 15: 173.

References

- S. Aker:** Cardiovascular Risk Factors and Diseases after Renal Transplantation International Urology and Nephrology 199830 (6), pp. 777-788.
- Sanders CE Jr, Curtis JJ.** Role of hypertension in chronic renal allograft dysfunction. *Kidney Int Suppl* 1995; 55: S43
- Santos AF, Keitel E, Bittar AE, et al.** Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. *Transplant Proc* 2001; 33: 1194.
- Sarasin FP, Giostra E, Hadengue A.** Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. *Am J Med* 1996; 101: 422.
- Sarwal M, Chua MS, Kambham N et al.** Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. *N Engl J Med* 2003; 349: 125-138.
- Satterwhite T, Chua MS, Hsieh SC et al.** Increased expression of cytotoxic effector molecules: Different interpretations for steroidbased and steroid-free regimens. *Pediatr Transplant* 2003; 7: 4-6.
- Sayegh MH, Lazarus JM.** Renal parenchymal disease and hypertension. In: *Current Management of Hypertension and Vascular Disease*. Cooke, JP, Frohlich, ED (Eds), Decker, Philadelphia, 1992, p. 76.
- Sayegh MH, Lazarus JM.** Renal parenchymal disease and hypertension. In: *Current Management of Hypertension and Vascular Disease*. Cooke, JP, Frohlich, ED (Eds), Decker, Philadelphia, 1992, p. 76.
- Scanlon-Kohlroser CA, Fan PY, Primack W, Stoff JS.** Primary varicella after transplantation. *Am J Kidney Dis* 2002; 39(6): 1310-2.
- Schiel R, Heinrich S, Steiner T et al.** Long-term prognosis of patients after kidney transplantation: a comparison of those with and without diabetes mellitus. *Nephrol Dial Transplant* 2005; 20: 611.
- Schmidt A, Oberbaum R.** Bacterial and fungal infections after kidney transplantation. *Curr Opin Urol* 1999; 9(1): 45-9.

References

- Schnitzler MA, Lowell JA, Hardinger KL et al.** The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal anplantation prior to the introduction of oral ganciclovir CMV prophylaxis. *Am J Transplant* 2003; 3: 445–451.
- Schold, JD, Kaplan, B, Baliga, RS, Meier-Kriesche, HU.** The broad spectrum of quality in deceased donor kidneys. *Am J Transplant* 2005; 5: 757.
- Schulman, LL, Htun, T, Staniloae, C, et al.** Pulmonary nodules and masses after lung and heart-lung transplantation. *J Thorac Imaging* 2000; 15: 173.
- Schweitzer EJ, Matas AJ, Gillingham KJ, et al.** Causes of renal allograft loss: Progress in the 1980's, challenges for the 1990's. *Ann Surg* 1991; 214(6): 679.
- Schwenger V, Keller T, Morath C, Krumme B, Zeier M.** Intrarenal Resistance Index (RI) and Pulsatility Index (PI) of renal allografts depend on vascular stiffness of the transplant recipient., *USAJ Am Soc Nephrol* (2005) 16: pp. F-P o988.
- Schwenger V, Korosoglou G, Hinkel UP, et al.)** Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy. *Am J Transplant*; 2006: 6: 609–615
- Seron D, Moreson F, Bover J, et al.** Early protocol renal allograft biopsies and graft outcome. *Kidney Int* 1997; 51: 310.
- Shah A, Kendall G, Demme R, et al.** Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. *Transplantation*. 2005; 80: 775.
- Shaver MJ, Bonsib SM, Abul-Ezz S, Barri YM.** Renal allograft dysfunction associated with cytomegalovirus infection. *Am J Kidney Dis* 1999; 34(5): 942-6.
- Sheil, AG.** Donor-derived malignancy in organ transplant recipients. *Transplant Proc* 2001; 33: 1827.
- Shiba N, Chan MC, Kwok BW, et al.** Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. *J Heart Lung Transplant*. 2004; 23: 155.

References

- Shihab FS, Andoh TF, Tanner AM, et al.** Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. *Kidney Int* 1999; 56:2147.
- Shihab FS, Bennett WM, Tanner AM, Andoh TF.** Angiotensin II blockade decreases TGF- β 1 and matrix proteins in cyclosporine nephropathy. *Kidney Int* 1997; 52: 660.
- Shihab FS, Yi H, Bennett, WM, Andoh, TF.** Effect of nitric oxide modulation on TGF- β 1 and matrix proteins in chronic cyclosporine nephrotoxicity. *Kidney Int* 2000; 58: 1174.
- Shokeir AA, Baker MA, el Diasty TA, et al.** Urological complications following live donor kidney transplantation: effect of urinary schistosomiasis. *Br J Urol* 1992; 70(3): 247-51.
- Sia I, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV.** Cytomegalovirus DNA load predicts relapsing CMV infection after solid organ transplantation. *J Infect Dis* 2000; 181: 717-20.
- Simon HB.** Mycobacterial and nocardial infections in the compromised host. In: Rubin RH, Young LS, eds. *Clinical approach to infection in the compromised host*, 2nd ed. New York, Plenum, 1988; pp 221-51.
- Siren Sezer, Ali Akcay, Fatma Nurhan Ozdemir, Eyup Kulah, Zubeyde Arat and Mehmet Haberal** CLINICAL TRANSPLANTATION 2004 volume 18 issue 6 pages 722-725.
- Smego RA, Moeller MB, Gallis HA.** Trimethoprim-sulfamethoxazole therapy for Nocardia infections. *Arch Intern Med* 1983; 143:711-8.
- Smit JV, De Sevaux RG, Blokx WA, et al.** Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. *J Am Acad Dermatol* 2004; 50: 189.
- Smith JR, Kubacki VB, Rakhit A, et al.** Chronic thromboxane synthesis inhibition with CGS 12970 in human cyclosporine nephrotoxicity. *Transplantation* 1993; 56:1422.
- Sobh MA, el Agroudy AE, Moustafa FE, Shokeir AA, el Shazly A, Ghoneim MA.** Impact of schistosomiasis on patient and graft outcome after kidney transplantation. *Nephrol Dial Transplant* 1992; 7(8): 858-64.

References

- Soulillou JP, Giral M.** Influence of graft characteristics on the outcome of kidney transplantation. *N Engl J Med* 2006; 354: 2060.
- Spieker C, Barenbrock M, Tepel M, Buchholz B, Rahn KH, Zidek W.** Pentamidine inhalation as a prophylaxis against *Pneumocystis carinii* pneumonia after therapy of acute renal allograft rejection with orthoclone (OKT3). *Transplant Proc* 1992; 24: 2602-3
- SRTR Report on the state of transplantation.** *Am J Transplant* 2006; 6: 843.
- Stallone G, Infante B, Schena A, et al.** Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. *J Am Soc Nephrol* 2005; 16: 3755.
- Stallone G, Schena A, Infante B, et al.** Sirolimus for Kaposi's sarcoma in renal-transplant recipients. *N Engl J Med* 2005; 352: 1317.
- Stamm AM, Dismukes WE, Simmons BP, et al.** Listeriosis in renal transplant recipients: report of an outbreak and review of 102 cases. *Rev Infect Dis* 1982; 4(3): 665-82.
- Stark K, Gunther M, Neuhaus R, et al.** Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. *J Infect Dis* 1999; 180(6): 2014-7.
- Statistics from the United Network for Organ Sharing (UNOS), 2001.**
- Stevens DA, Pier AC, Beaman BL, Morozumi PA, Lovett IS, Houang ET.** Laboratory evaluation of an outbreak of nocardiosis in immunocompromised hosts. *Am J Med* 1981; 71(6): 928-34.
- Stewart T, Tsai SC, Grayson H, et al.** Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. *Lancet* 1995; 346: 796.
- Stigant, CE, Cohen, J, Vivera, M, Zaltzman, JS.** ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. *Am J Kidney Dis* 2000; 35: 58.
- Stokes KY, Abdih HK, Kelly CJ, et al.** Thermotolerance attenuates ischemia-reperfusion induced renal injury and increased expression of ICAM-1. *Transplantation* 1996; 62: 1143.

References

- Sulanc E, Lane J, Puumala S et al.** New-onset diabetes after kidney transplantation: An application of 2003 International Guidelines. *Transplantation*. 2005; 80: 945.
- Suleiman AB, Musa Z, Morad Z.** Tuberculosis in living related donor renal transplant recipients. *Ann Acad Med Singapore* 1988; 17(3): 454-6.
- Sumrani N, Delaney V, Ding Z, et al.** Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. *Transplant Proc* 1991; 23: 1249.
- Swann PF, Waters TR, Moulton DC, et al.** Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. *Science* 1996; 273: 1109.
- Taioli E, Piselli P, Arbustini E, et al.** Incidence of second primary cancer in transplanted patients. *Transplantation* 2006; 81: 982.
- Takai K, Tollemar J, Wilczek HE, Groth CG.** Urinary tract infections following renal transplantation. *Clin Transplant* 1998; 12(1): 19-23.
- Takashi Taguchi and Mohammed Shawkat Razzaque**, modified from the book *Chronic Allograft Failure: Natural History, Pathogenesis, Diagnosis and Management*
- Takeda Y, Miyamori I, Wu P, et al.** Effects of an endothelin receptor antagonist in rats with cyclosporine- induced hypertension. *Hypertension* 1995; 26: 932.
- Tang S, Cheng IK, Leung VK, et al.** Successful treatment of hepatitis C after kidney transplantation with combined IFNalpha 2b and ribavirin. *J Hepatol* 2003; 39(5):875-8.
- Terasaki, PI, Cecka, JM, Cho, Y, et al.** Overview. In: *Clinical Transplants*, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles, 1989, p. 585.
- Terasaki PI, Cecka JM, Gjertson DW, et al.** Risk rate and long-term kidney transplant survival. In: *Clinical Transplants 1996*, Terasaki, PI (Ed), UCLA Tissue Typing Laboratory, Los Angeles 1997, p. 443.

References

- Terasaki PI, Ozawa M.** Predicting kidney graft failure by HLA antibodies: A prospective trial. *Am J Transplant* 2004; 4: 438.
- Terasaki, PI, Ozawa, M.** Predictive Value of HLA Antibodies and Serum Creatinine in Chronic Rejection: Results of a 2-year Prospective Trial. *Transplantation* 2005; 80: 1194.
- Teutonico, A, Schena, P, Di Paolo, S.** Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. *J Am Soc Nephrol.* 2005; 16: 3121.
- Textor SC, Canzanello VJ, Taler SJ, et al.** Cyclosporine-induced hypertension after transplantation. *Mayo Clin Proc* 1994; 69: 1182.
- Textor SC, Canzanello VJ, Taler SJ, et al.** Cyclosporine-induced hypertension after transplantation. *Mayo Clin Proc* 1994; 69: 1182.
- Thomas SE, Andoh TF, Pichler RH, et al.** Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. *Kidney Int* 1998; 53: 897.
- Tolkoff-Rubin NE, Rubin RH.** Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. *Infect Dis Clin North Am* 1997; 11(3): 707-17.
- Torre-Cisneros J, Caston JJ, Moreno J, et al.** Tuberculosis in the transplant candidate: importance of early diagnosis and treatment. *Transplantation* 2004; 77: 1376.
- Toupance O, Bouedjoro-Camus MC, Carquin J, et al.** Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. *Transpl Int* 2000; 13(6): 413-9.
- Trofe J, Buell JF, Woodle ES, et al.** Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or Non-Hodgkin lymphoma. *Transplantation* 2004; 78: 972.
- Troppmann C, Gillingham KJ, Gruessner RW, et al.** Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. *Transplantation* 1996; 61: 1331.

References

- Tullius SG, Tilney NL.** Both alloantigen-dependent and -independent factors influence chronic allograft rejection. *Transplantation* 1995; 59: 313.
- Tullius SG, Volk HD, Neuhaus P.** Transplantation of organs from marginal donors. *Transplantation* 2001; 72: 1341.
- Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G.** Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. *Transplant Proc* 2000; 32: 622.
- Turk T, Pietruck F, Dolff S, et al.** Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. *Am J Transplant* 2006; 6: 842
- UNOS Statistics from the United Network for Organ Sharing (UNOS), 2001.**
- van den Berg AP, van Son WJ, Haagsma EB, et al.** Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. *Transplantation* 1993; 55(4): 847-51.
- van der Heide JJ, Bilo HJ, Donker JM, et al.** Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. *N Engl J Med* 1993; 329: 769.
- Vandermarliere A, Van Audenhove A, Peetermans WE, Vanrenterghem Y, Maes B.** Mycobacterial infection after renal transplantation in a Western population. *Transpl Infect Dis* 2003; 5(1): 9-15.
- Vanrenterghem Y, et al.** Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. *Transplantation* 2000; 70: 1352.
- Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W.** Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. *Transplantation* 1986; 42(4): 376-9.

References

- Vesco L, Busson M, Bedrossian J, et al.** Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. *Transplantation* 1996; 61: 1475.
- Villaneuva, G, Baldwin, D.** Rosiglitazone therapy of posttransplant diabetes mellitus. *Transplantation* 2005; 80: 1402.
- Vlahakos, DV, Canzanello, VJ, Madaio, MP, Madias, NE.** Enalapril-associated anemia in renal transplant recipients treated for hypertension. *Am J Kidney Dis* 1991; 17: 199.
- Wagener MM, Yu VL.** Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. *Am J Infect Control* 1992; 20(5): 239-47.
- Wang Y, Pratt JR, Hartley B, et al.** Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. *Kidney Int* 1997; 52: 371.
- Watschinger, B, Sayegh, MH.** Endothelin in organ transplantation. *Am J Kidney Dis* 1996; 27: 151.
- Webb NJ.** Immunization against varicella in end stage and pre-end stage renal failure. *Arch Dis Child* 2000; 82: 141-3.
- Webb MC, Compton F, Andrews PA, Koffman CG.** Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. *Transplant Proc* 1997; 29: 828.
- Weir MR, Fink JC.** Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. *Am J Kidney Dis* 1999; 34: 1.
- Wheat LJ, Kohler RB, Tewari RP.** Diagnosis of disseminated histoplasmosis by detection of *Histoplasma capsulatum* antigen in serum and urine specimens. *N Engl J Med* 1986; 314: 83-8.
- Wigmore SJ, Seeney FM, Pleass HC, et al.** Kidney damage during organ retrieval: data from UK National Transplant Database. *Kidney Advisory Group. Lancet* 1999; 354: 1143.
- Wilczek H, Kallings I, Nystrom B, Hoffner S.** Nosocomial Legionnaires' disease following renal transplantation. *Transplantation* 1987; 43(6): 847-851.

References

- Wilkinson A, Davidson J, Dotta F, et al.** Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clin Transplant* 2005; 19: 291.
- Williams D, Haragsim, L.** Calcineurin nephrotoxicity. *Adv Chronic Kidney Dis* 2006; 13: 47.
- Wilson JP, Turner HR, Kirchner KA, Chapman SW.** Nocardial infections in renal transplant recipients. *Medicine (Baltimore)* 1989; 68(1): 38-57.
- Winkelmayr WC, Kramar R, Curhan GC, et al.** Fasting Plasma Total Homocysteine Levels and Mortality and Allograft Loss in Kidney Transplant Recipients: A Prospective Study. *J Am Soc Nephrol* 2005; 16: 255.
- Woo YM, Gill JS, Johnson N, et al.** The advanced age deceased kidney donor: Current outcomes and future opportunities. *Kidney Int* 2005; 67: 2407
- Woodward RS, Schnitzler MA, Baty J, et al.** Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. *Am J Transplant* 2003; 3: 590.
- Wu MJ, Lian JD, Yang CR, et al.** High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. *Am J Kidney Dis* 2004; 43: 1091.
- Yokoyama I, Uchida K, Kobayashi T, et al.** Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. *Clin Transplant* 1994; 8: 101.
- Zamora I, Simon JM, De Silva ME, Piqueras AI.** Attenuated varicella virus vaccine in children with renal transplants. *Pediatr nephrol* 1994; 8: 190-2.